Evotec and Vifor Pharma Sign Major Cooperation Agreement

(Thomson Reuters ONE) - Evotec AG / Evotec and Vifor Pharma Sign Major Cooperation Agreement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. * Development of preclinical candidate in the field of anaemia * Evotec to provide integrated biology, chemistry and preclinical development activities * Project worth in excess of EUR 5.5 millionHamburg, Germany - 2 February 2010: Evotec AG (Frankfurt Stock Exchange: EVT,TecDAX) today announced that it has signed an agreement with Vifor Pharma.Evotec will provide and project manage the discovery activities to identify apreclinical candidate for the treatment of anaemia. Due to confidentialityreasons both companies will not reveal further details about the researchproject.The agreement applies Evotec's integrated drug discovery expertise andtechnologies to progress novel small molecules for the treatment of anaemia fromdiscovery into lead optimisation.Evotec will use scientists based at both its European and Indian sites coveringin vitro biology, medicinal chemistry, in vitro and in vivo pharmacology and theprogramme will be funded through research funding and success based milestones.Dr Werner Lanthaler, CEO of Evotec, commented: "This agreement represents agreat step forward in our business model, as we are committed to identifying apreclinical candidate within an agreed budget. This will allow us to fullyintegrate and leverage all of our research sites and scientists to efficientlydeliver a preclinical candidate to Vifor Pharma and clearly demonstrates thecomplete integrated drug discovery capability we have.""We have a high regard for Evotec's drug discovery and development expertise andthe capabilities and technologies they will use to progress our project. Theyhave a proven expertise in drug discovery and development and we look forward toachieving success with Evotec" said Dr David Ebsworth, CEO at Vifor Pharma.About AnaemiaAnaemia is a condition in which the haemoglobin concentration in the blood isbelow a defined level, resulting in a reduced oxygen-carrying capacity of redblood cells. Iron deficiency is the most common nutritional disorder in theworld and the most common cause of anaemia. There are an estimated 700 millionpeople in the world with iron deficiency anaemia. Symptoms of irondeficiency/anaemia are fatigue, pallor, hair loss, irritability, weakness,brittle or grooved nails etc.Contact: Dr Werner Lanthaler, Chief Executive Officer,Evotec AG, Tel.: +49.(0)40.56081-242,  werner.lanthaler(at)evotec.comForward-looking statementsInformation set forth in this press release contains forward-looking statements,which involve a number of risks and uncertainties. Such forward-lookingstatements include, but are not limited to, statements about our expectationsand assumptions concerning our strategic collaborations, our regulatory,clinical and business strategies, the progress of our clinical developmentprogrammes and management's plans, objectives and strategies. These statementsare neither promises nor guarantees, but are subject to a variety of risks anduncertainties, many of which are beyond our control, and which could causeactual results to differ materially from those contemplated in theseforward-looking statements. In particular, the risks and uncertainties include,among other things: risks that product candidates may fail in the clinic or maynot be successfully marketed or manufactured; the risk that we will not achievethe anticipated benefits of our collaborations, partnerships and acquisitions inthe timeframes expected, or at all; risks relating to our ability to advance thedevelopment of product candidates currently in the pipeline or in clinicaltrials; our inability to further identify, develop and achieve commercialsuccess for new products and technologies; the risk that competing products maybe more successful; our inability to interest potential partners in ourtechnologies and products; our inability to achieve commercial success for ourproducts and technologies; our inability to protect our intellectual propertyand the cost of enforcing or defending our intellectual property rights; ourfailure to comply with regulations relating to our products and productcandidates, including FDA requirements; the risk that the FDA may interpret theresults of our studies differently than we have; the risk that clinical trialsmay not result in marketable products; the risk that we may be unable tosuccessfully secure regulatory approval of and market our drug candidates; andrisks of new, changing and competitive technologies and regulations in the U.S.and internationally.The list of risks above is not exhaustive. Our most recent Annual Report on Form20-F, filed with the Securities and Exchange Commission, and other documentsfiled with, or furnished to the Securities and Exchange Commission, containadditional factors that could impact our businesses and financial performance.We expressly disclaim any obligation or undertaking to release publicly anyupdates or revisions to any such statements to reflect any change in ourexpectations or any change in events, conditions or circumstances on which anysuch statement is based.[HUG#1379397] --- End of Message --- Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480;ISIN: DE0005664809 ;Index:MIDCAP,Prime All Share,CDAX,TECH All Share,HDAX;Listed: Freiverkehr in B? Stuttgart,Freiverkehr in Hanseatische Wertpapierb? zu Hamburg,Freiverkehr in B? Berlin,Freiverkehr in B? D?ldorf,Freiverkehr in Bayerische B? M?en,Freiverkehr in Nieders?sische B? zu Hannover,Prime Standard in Frankfurter Wertpapierb?,Regulierter Markt in Frankfurter Wertpapierb?; PDf of Press release: http://hugin.info/131215/R/1379397/339460.pdf

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: hugin
Datum: 02.02.2010 - 01:29 Uhr
Sprache: Deutsch
News-ID 1009888
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

Hamburg

Phone:

Kategorie:

Business News

Anmerkungen:


Diese Pressemitteilung wurde bisher 124 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Evotec and Vifor Pharma Sign Major Cooperation Agreement
"
steht unter der journalistisch-redaktionellen Verantwortung von

Evotec AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von Evotec AG